Advertisement US Pharma Firm Chooses OmniComm's TrialMaster For Phase III Study On CNS Disorders - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

US Pharma Firm Chooses OmniComm’s TrialMaster For Phase III Study On CNS Disorders

OmniComm Systems, a global provider of eClinical solutions, was chosen by a pharmaceutical company to provide its EDC Solution TrialMaster for a Phase III study of a drug to test a central nervous system disorder.

The contract is for in excess of $200,000 and total revenue generated from this customer exceeds $750,000 over the last six months.

Stephen Johnson, COO of OmniComm Systems, said: OmniComm continues to enhance clinical trial outcomes through TrialMaster. We are gratified that another customer has entrusted us with managing their data in a pivotal study. Our ability to attract and retain leading pharmaceutical companies has contributed to a strong start in 2010.

OmniComm Systems provides internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct clinical trial research. OmniComm Systems has US headquarters in Fort Lauderdale, Florida and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the UK. It also has offices throughout the Europe and US.